Narayan P, Prowell TM, Gao JJ, Fernandes LL, et al. FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res 2020 Nov 9. pii: 1078-0432.CCR-20-3652.
PMID: 33168657